Hepatitis C treatment at a Swedish needle exchange program, a successful model of care - the ACTIONNE study.

[1]  O. Falade-Nwulia,et al.  Hepatitis C treatment uptake among people who inject drugs in the oral direct‐acting antiviral era , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[2]  G. Dore,et al.  Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. , 2019, Journal of hepatology.

[3]  N. Luhmann,et al.  We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade , 2019, Journal of internal medicine.

[4]  M. Heo,et al.  Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy , 2019, Annals of Internal Medicine.

[5]  J. Leung,et al.  Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs , 2018, Addiction.

[6]  G. Ioannou,et al.  What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? , 2019, Gastroenterology.

[7]  P. Read,et al.  Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. , 2018, The International journal on drug policy.

[8]  G. Dore,et al.  Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. , 2018, The lancet. Gastroenterology & hepatology.

[9]  D. Nelson,et al.  Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. , 2017, Annals of internal medicine.

[10]  G. Dore,et al.  Epidemiology and natural history of HCV infection , 2013, Nature Reviews Gastroenterology &Hepatology.

[11]  K. Kielland,et al.  All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. , 2013, Journal of hepatology.